<unk>  is a janus kinase inhibitor (JAK inhibitor) with selectivity for subtypes JAK1 and JAK2.<unk>  inhibits dysregulated JAK signaling associated with myelofibrosis. JAK1 and JAK2 recruit signal transducers and activators of transcription (STATs) to cytokine receptors leading to modulation of gene expression.
Ruxolitinib
Ibrutinib
Bosutinib
Imatinib
Ranibizumab
Abrocitinib
Ceritinib
Ponatinib